Amit Chokshi
Amit Chokshi
Send Message
Amit Chokshi
Stop FollowingAmit Chokshi
View as an RSS Feed
View Amit Chokshi's Articles BY TICKER:
-
Value Investing Gets Its Comeuppance
on Sun, May 17, 2009 • 4 Comments
-
Kass' Short Bet on Berkshire Falls Short of Reason
- Two Questions for Jarden's 2008 Year End
- The State of Financial Markets and U.S. Dollar in 2009, Part II
-
The State of Financial Markets and U.S. Dollar in 2009, Part I
-
Some Investment Themes for 2009
-
Hanes Unfairly Treated by Mistaken Association with Gildan
- Q4 Warning and Moody's Support My Jarden Short Thesis
-
Analyst Estimates for Jarden in 2009 Look Ridiculously Optimistic
-
BioScrip's Time to Right the Ship Is Running Out
-
Lifeway's Valuation Doesn't Look Justified
-
BioScrip Investors Would Welcome a Strategic Buyer
-
Priceline: More Headwinds Ahead
- BioScrip's Inept Management Continues to Blunder
- Crocs: It's the Product, Not the Economy
-
BioScrip Management, Board Should Be Shown the Door
-
BioScrip 'Rewards' Investors with Poor Corporate Governance
-
7 Reasons Why NRG’s Offer for Calpine is Laughable
-
The Short Case on Priceline
-
Ecology and Environment: Growing Trading Volume and Institutional Interest
-
Downey Financial on Shaky Ground
-
Citigroup Bottoming - Plus Some Free Advice for Meredith Whitney
-
Costco: Overpriced for Its Growth Rate
- Why I'm Not Long Downey Financial
- Jarden's 'Rope a Dope' Investor Relations
- Cramer Doing a Mea Culpa on Downey Financial?
-
Target: Skeptical of Ackman's Valuation
- Is Sally Beauty Holdings Being Manipulated?
- @VIC: Noven Pharmaceuticals - Long Idea
-
Jarden Remains a Compelling Short
- Downey Financial/Hilltop Holdings: Billionaire Pump and Dump?
-
E*Trade, Wells Fargo and Downey: 'Subprime' Problems With Prime Loans
